June 3, 2019
Via: The Medical NewsIn an international, randomized, phase III clinical trial, researchers added an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) to standard endocrine therapy for women with advanced HR-positive/HER2-negative breast cancer. The researchers report that adding the CDK inhibitor significantly increased […]
March 28, 2024
March 15, 2024